XML 58 R19.htm IDEA: XBRL DOCUMENT v3.20.2
License and Collaboration Agreements (Tables)
 6 Months Ended
Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
License, Collaboration and Other Revenue
In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):
Three months ended June 30,Six months ended June 30,
Partner
Drug or Drug Candidate
2020201920202019
Bristol-Myers Squibb Company
Bempegaldesleukin$25,000  $—  $50,000  $—  
Eli Lilly and Company
NKTR-358
—  1,200  1,259  3,700  
Amgen, Inc.
Neulasta®
1,250  1,250  2,500  2,500  
Other25  85  31  539  
License, collaboration and other revenue
$26,275  $2,535  $53,790  $6,739  
Changes in Deferred Revenue Balance from Collaboration Agreements
The following table presents the changes in our deferred revenue balance from our collaboration agreements during the six months ended June 30, 2020 (in thousands):
Six Months Ended June 30, 2020
Deferred revenue—December 31, 2019$8,071  
Recognition of previously unearned revenue(3,790) 
Deferred revenue—June 30, 2020$4,281